Literature DB >> 25081100

The interaction of active substance use, depression, and antiretroviral adherence in methadone maintenance.

Howard Newville1, Karina M Berg, Jeffrey S Gonzalez.   

Abstract

BACKGROUND: Adherence to highly active antiretroviral therapy (HAART) remains crucial in successfully treating HIV. While active substance use and depression are both associated with each other and with HAART nonadherence, little is known about their interaction. An understanding of the interaction of substance use and depressive symptoms on HAART adherence can inform adherence-enhancing interventions as well as interventions that target substance use and depression.
PURPOSE: We tested an interaction between substance use and depression on HAART adherence among methadone maintenance patients.
METHOD: We assessed substance use, depressive symptoms, and HAART adherence among 100 HIV-infected individuals receiving methadone maintenance in The Bronx, New York. Regressions were performed on adherence using an interaction term comprised of substance use and depressive symptoms. MODPROBE was used to assess significant interactions.
RESULTS: Any use of illicit substances was associated with HAART nonadherence (p = 0.043). Cannabis was the single substance of abuse most strongly associated with nonadherence (p = 0.003). Depressive symptoms approached significance in bivariate analysis (p = 0.066). In regression analysis, a significant interaction was found between illicit substance use and depressive symptoms [OR (95% CI) 1.23 (1.06-1.44), p = 0.007], where illicit substance use was associated with nonadherence in individuals with lower depressive symptoms, but not among those with depressive symptoms at higher levels. No individual substances interacted with depressive symptoms on adherence.
CONCLUSION: Though substance use and depressive symptoms interacted on HAART adherence, they did not have a synergistic effect. Continued substance use (51% of the sample) suggests an unmet need for treatment, even in methadone maintenance. Further examinations of the interplay of substance use and depression on HAART adherence are warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25081100     DOI: 10.1007/s12529-014-9429-z

Source DB:  PubMed          Journal:  Int J Behav Med        ISSN: 1070-5503


  79 in total

1.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

2.  Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users.

Authors:  Julia H Arnsten; Xuan Li; Yuko Mizuno; Amy R Knowlton; Marc N Gourevitch; Kathleen Handley; Kelly R Knight; Lisa R Metsch
Journal:  J Acquir Immune Defic Syndr       Date:  2007-11-01       Impact factor: 3.731

3.  Effectiveness of highly active antiretroviral therapy among HIV-1 infected women.

Authors:  S J Gange; Y Barrón; R M Greenblatt; K Anastos; H Minkoff; M Young; A Kovacs; M Cohen; W A Meyer; A Muñoz
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

4.  Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003).

Authors:  Patrick Peretti-Watel; Bruno Spire; France Lert; Yolande Obadia
Journal:  Drug Alcohol Depend       Date:  2006-04       Impact factor: 4.492

5.  Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment.

Authors:  V L King; M S Kidorf; K B Stoller; R K Brooner
Journal:  J Addict Dis       Date:  2000

6.  Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users.

Authors:  M P Carrieri; M A Chesney; B Spire; A Loundou; A Sobel; G Lepeu; J P Moatti
Journal:  Int J Behav Med       Date:  2003

7.  Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits.

Authors:  M D Glantz; J C Anthony; P A Berglund; L Degenhardt; L Dierker; A Kalaydjian; K R Merikangas; A M Ruscio; J Swendsen; R C Kessler
Journal:  Psychol Med       Date:  2008-12-02       Impact factor: 7.723

8.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

9.  Depression, substance abuse and other contextual predictors of adherence to antiretroviral therapy (ART) among Haitians.

Authors:  Robert Malow; Jessy G Dévieux; Judith A Stein; Rhonda Rosenberg; Michele Jean-Gilles; Jennifer Attonito; Serena P Koenig; Giuseppe Raviola; Patrice Sévère; Jean W Pape
Journal:  AIDS Behav       Date:  2013-05

10.  Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep.

Authors:  Margaret Haney; Erik W Gunderson; Judith Rabkin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

View more
  7 in total

1.  Marijuana use and viral suppression in persons receiving medical care for HIV-infection.

Authors:  Chukwuemeka N Okafor; Zhi Zhou; Larry E Burrell; Natalie E Kelso; Nicole E Whitehead; Jeffery S Harman; Christa L Cook; Robert L Cook
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-11       Impact factor: 3.829

2.  Medication adherence in people dually treated for HIV infection and mental health conditions: test of the medications beliefs framework.

Authors:  Seth C Kalichman; Jennifer Pellowski; Christopher Kegler; Chauncey Cherry; Moira O Kalichman
Journal:  J Behav Med       Date:  2015-04-03

3.  The Association Between Marijuana Use and HIV Continuum of Care Outcomes: a Systematic Review.

Authors:  LaTrice Montgomery; Kara Bagot; Jennifer L Brown; Angela M Haeny
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

4.  Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis.

Authors:  Louise Foley; James Larkin; Richard Lombard-Vance; Andrew W Murphy; Lisa Hynes; Emer Galvin; Gerard J Molloy
Journal:  BMJ Open       Date:  2021-09-02       Impact factor: 3.006

5.  Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study.

Authors:  Anees Bahji; Yu Li; Rachel Vickers-Smith; Stephen Crystal; Robert D Kerns; Kirsha S Gordon; Alexandria Macmadu; Melissa Skanderson; Kaku So-Armah; Minhee L Sung; Fiona Bhondoekhan; Brandon D L Marshall; E Jennifer Edelman
Journal:  Int J Environ Res Public Health       Date:  2022-05-06       Impact factor: 4.614

6.  Polysubstance use and adherence to antiretroviral treatment in the Miami Adult Studies on HIV (MASH) cohort.

Authors:  Abraham Degarege; Karl Krupp; Javier Tamargo; Sabrina Sales Martinez; Adriana Campa; Marianna Baum
Journal:  AIDS Care       Date:  2021-03-05

7.  Association between cannabis use and treatment outcomes in patients receiving methadone maintenance treatment: a systematic review protocol.

Authors:  Laura Zielinski; Meha Bhatt; Rebecca B Eisen; Stefan Perera; Neera Bhatnagar; James MacKillop; Meir Steiner; Stephanie McDermid Vaz; Lehana Thabane; Zainab Samaan
Journal:  Syst Rev       Date:  2016-08-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.